Finasteride Tablet, Film Coated
Product Images NDC 57237-062

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 57237-062). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' comparing mean change from baseline plus or minus one standard error in symptom score over four years between Finasteride and Placebo groups. The graph shows Finasteride with a decreasing symptom score over time, while Placebo remains relatively stable. Sample sizes decrease slightly over the years.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph showing the percent of patients having surgery for BPH, including TURP, over 48 months of observation time. It compares two groups: Finasteride and Placebo. The Placebo group's surgery rates increase steadily to about 10%, while the Finasteride group's rates rise more slowly to about 5%. Below the graph are tables showing cumulative events and number at risk per year for both groups.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' comparing finasteride and placebo groups over a 48-month observation period. The vertical axis shows the percent of patients (0% to 15%), and the horizontal axis shows time in months (0 to 48). The graph includes cumulative event numbers and patients at risk per year for each group below the plot.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

Figure 4 is a line graph showing mean percent change from baseline in prostate volume with standard error bars over a 4-year period in a long-term efficacy and safety study. Two groups are compared: placebo and finasteride, with data points at baseline, year 1, year 2, year 3, and year 4. The x-axis shows time (baseline to year 4), and the y-axis shows mean percent change from baseline ranging from -20% to 20%. Sample sizes for each group at each time point are indicated below the graph.*

FDA Label Image

Package Label-principal Display Panel (5 mg (30 Tablets Bottle))

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing percent with event on the y-axis and years from randomization on the x-axis. The graph compares four treatment groups: Placebo, Finasteride, Doxazosin, and Combination, each represented by different line markers, illustrating their cumulative incidence over approximately 5.5 years.*

FDA Label Image

Finasteride Fig6

Finasteride Tablets, USP 5 mg film-coated tablets label from Rising Pharma Holdings, Inc. The label includes dosage information, storage instructions, and a warning against use by women and children. The package contains 30 tablets for oral administration. Distributed by Rising Health, LLC, made in India.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of Finasteride, showing its molecular arrangement with multiple rings, functional groups including a keto group and an amide moiety with a tert-butyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.